Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy.
about
Renal tumours: long-term outcomeCancer survivors in the United States: a review of the literature and a call to actionImpact of late radiation effects on cancer survivor children: an integrative reviewPhase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trialsLate effects of treatment for wilms tumorCost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.Increasing cardiomyopathy screening in at-risk adult survivors of pediatric malignancies: a randomized controlled trial.Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.Review of cardiotoxicity in pediatric cancer patients: during and after therapy.Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohortLate cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells.Prevention of Doxorubicin cardiopathic changes by a benzyl styryl sulfone in miceCardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemiaRole of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclinesCancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.Anthracycline cardiotoxicity.Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy: A Cross-sectional StudyAnthracycline cardiotoxicity in childhood.Tissue Doppler Imaging and Focal, Late-Onset Anthracycline-Induced Cardiovascular Disease in Long Term Survivors of Childhood Cancer: A Research ArticleReview: doxorubicin delivery systems based on chitosan for cancer therapy.Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in ratsComparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion.Cardiotoxicity of childhood cancer treatment: update and current knowledge on long-term follow-up.Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.Current views on anthracycline cardiotoxicity.Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.Plasma natriuretic peptides levels and echocardiographic findings in late subclinical anthracycline toxicity.Rehabilitative exercise in a rat model of doxorubicin cardiotoxicity.The impact of doxorubicin and dexrazoxane injection of prepubertal female rats on pregnancy outcome and cardiac function postpartum.Cardiac response to doxorubicin and dexrazoxane in intact and ovariectomized young female rats at rest and after swim training.The effect of oxidized low-density lipoprotein (ox-LDL) on radiation-induced endothelial-to-mesenchymal transition.Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicityLipid Emulsion Inhibits the Late Apoptosis/Cardiotoxicity Induced by Doxorubicin in Rat Cardiomyoblasts
P2860
Q26828577-8A4C85BD-6DAD-4FAA-86ED-C8A84E676CB4Q26865247-02EF98C8-B9C8-48C9-AA0C-18249F0B9EE3Q28085523-9691E856-60F5-42F0-81C2-FC113FAD178FQ33423926-D7E2C3DF-A29F-477F-99F2-13C2EBDBBC11Q33619867-67E19BC3-7A38-4A24-B2E8-39F1D948E655Q33691101-CB861DE4-9F07-48F2-AA0A-09C7ED687C6DQ33815037-6D775B75-F20E-495E-87D2-50D307607558Q34611645-31DDFC3B-DFD9-4B93-8AC7-54A985D93A82Q34717844-AA29CFAA-6394-436C-8C0D-14C86F454B04Q35008126-EA39E095-B528-4F32-A6BF-226CBD901D80Q35076156-52EAB05B-3F10-47E3-A29E-3941A9C953F8Q35699184-D21034A7-30A6-4FD2-ADF3-6BF84188A279Q35757419-9449C5AC-3BE8-4753-9CDB-9EA5D79E0F61Q35797623-74CC4CCE-13C8-491C-ABBE-A3235BE443E9Q35903199-489A2F71-CC53-404C-B9CF-10F16BE1ADFFQ36030052-CFB81AB1-2F21-4D99-8ED3-4C9038FD3F22Q36049496-550878B4-55DD-48A0-A2AE-75AAB9986EF6Q36416745-A9B9F9F0-1308-476C-A8DD-0DB7A99A870AQ36451899-C9147DDD-3D21-4ECC-8487-5C4120D7BA37Q36612320-E61E116C-BF5F-4E73-84F5-5594D08056ECQ36624983-8CD5BDD2-88E4-42FD-8006-E43A2BBA698AQ36732654-DD265979-BB32-4109-821D-05EE57EE2AB7Q37165394-D2288B18-EF4C-4BE7-A132-AB58D498CB6AQ37266712-25B34860-B103-425D-817B-4A409C638ADEQ37380142-5912AF31-C461-412D-B3B7-A0C617575052Q37729947-2F2A7B1E-83A6-49EC-BFF9-1C8E42179782Q37783289-3855281A-1AFF-4276-852A-8D4EF02BC152Q38021523-2B65539A-C83C-4A48-8165-80FF55E6DCC3Q38079197-44BA119D-0CE5-4543-80DE-9D18F40F6513Q38205702-9817F25B-5814-401A-A61B-9689CF5A0FD8Q38845535-0C9FBCA0-78BC-4BB6-971D-BCDD1609234FQ39012650-3FBFF2B8-2B23-43E5-A849-2BFF66A38C11Q48809762-D9C342B3-9233-4505-855B-43A14F397330Q51277742-8A853214-33F7-4B02-A2B6-3DF48BC293BFQ51294069-0A4AE9A3-EB18-47AB-9396-667491F3C6B6Q51350978-FBD09D05-9CBE-4685-BE07-00CA50248404Q53126395-B002DFFC-6CBC-41C8-A6BB-B8F65B9098A0Q58696664-1626B8B8-73A6-444E-B67B-5B77B74EC854Q58708873-10209638-44DD-4E0E-89F5-490414BB226C
P2860
Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cardiac abnormalities 15 years ...... t the Institut Gustave Roussy.
@ast
Cardiac abnormalities 15 years ...... t the Institut Gustave Roussy.
@en
type
label
Cardiac abnormalities 15 years ...... t the Institut Gustave Roussy.
@ast
Cardiac abnormalities 15 years ...... t the Institut Gustave Roussy.
@en
prefLabel
Cardiac abnormalities 15 years ...... t the Institut Gustave Roussy.
@ast
Cardiac abnormalities 15 years ...... t the Institut Gustave Roussy.
@en
P2093
P2860
P356
P1476
Cardiac abnormalities 15 years ...... t the Institut Gustave Roussy.
@en
P2093
A Shamsaldin
F de Vathaire
J Lebidois
O Hartmann
O Sakiroglu
P2860
P2888
P356
10.1038/SJ.BJC.6601904
P407
P577
2004-07-01T00:00:00Z